BioNexus Gene Lab Corp. BGLC
1.39
(0.09)
(6.08%)
as of 25 Sep
- Market cap
- $4.3M
- P/E
- 0.0×
Follow BGLC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (33.66%) | (36.62%) | (35.24%) | (28.35%) |
+8 more TTM periods Free account |
|
| (28.38%) | (31.37%) | (30.32%) | (24.68%) | ||
ROIC |
(37.16%) | (43.22%) | (40.50%) | (37.43%) | |
Return on Tangible Assets |
(45.43%) | (48.60%) | (45.73%) | (35.23%) | |
Average Days of Receivables |
21.68 | 15.84 | 31.90 | 66.51 | |
Free Cash Flow per Share |
(0.35) | (0.49) | (1.01) | (1.46) | |
Free Cash Flow |
(0.85) | (1.19) | (1.88) | (2.62) | |
Capital Expenditures |
(0.01) | (0.03) | (0.04) | (0.04) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(7.46%) | (9.60%) | (14.53%) | (26.57%) | |
Accounts Receivable Turnover |
2.73 | 5.32 | 6.42 | 5.85 | |
Accounts Payable Turnover |
4.60 | 6.07 | 12.25 | 0.00 | |
Inventory Turnover |
2.93 | 4.95 | 6.14 | 6.73 | |
Average Days of Payables |
1.05 | 0.17 | 0.13 | 0.00 | |
Days of Inventory on Hand |
86.95 | 53.29 | 38.96 | 45.58 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1.73% | 1.00% | 0.68% | 0.60% | |
Selling, General and Administrative Expense of Revenue |
87.11% | 66.18% | 54.77% | 40.75% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 13.29% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.33 | 0.40 | 0.62 | 1.12 | |
Depreciation/Fixed assets |
0.11 | 0.11 | 0.11 | 0.11 | |
Capex/Depreciation |
(0.04) | (0.16) | (0.22) | (0.24) | |
Revenue per Share |
1.29 | 2.20 | 4.00 | 5.27 | |
Operating CF per Share |
(0.35) | (0.48) | (0.99) | (1.44) | |
Capex per Share |
0.00 | (0.01) | (0.02) | (0.02) | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Net Profit Margin |
(82.36%) | (54.70%) | (40.20%) | (24.27%) |
Columns are period end dates